Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of ''New Uses''

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 84-87

  Amara, Leonard ^a,b   Viveiros, Miguel ^a,b   Molnar, Joseph ^b   Kristiansen, Jette E ^b,c  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cure; Ex vivo activities; Extensive drug resistance (XDR TB); In vitro activities; In vivo activities; Multidrug resistance (MDR TB); Patent as "new use"; Thioridazine

Indexed keywords

ANTIBIOTIC AGENT; CHLORPROMAZINE; ISONIAZID; PHENOTHIAZINE; RIFAMPICIN; THIORIDAZINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; COMPASSIONATE USE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESEARCH; DRUG USE; ESSENTIAL GENE; EX VIVO STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE EXPRESSION REGULATION; HUMAN; IN VIVO STUDY; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; QUALITY OF LIFE; SIDE EFFECT; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT;

EID: 79959996814     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064542     Document Type: Article

References (31)

1. Amaral L, Martins M, Viveiros M. Phenothiazines as Anti- MDRTB tubercular agents. Infect Disorders Dis Targets 2007; 7: 257-265.
2. Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial - efflux pumps. Curr Drug Targets 2008; 9: 816-819.
3. Wallace D. The resurgence of tuberculosis in New York City: A mixed hierarchically and spatially diffused epidemic. Am J Public Health 1994; 84:1000-1002.
4. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drugresistant tuberculosis: A threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
5. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 1997; 40: 319-327.
6. Amaral L, Kristiansen JE. Phenothiazines: An alternative to conventional management of suspect multidrug resistant tuberculosis. Int J Antimicrob Agents 2000; 14:173-176.
7. Shubin H, Heiken CA, Glaskin A, Pennes E, Arsenian J. Chlorpromazine as an adjunct in managing tuberculous patients. Int Rec Med Gen Pract Clin 1957; 170: 369-373.
8. Molnár J, Béládi I, Földes I. Studies on antituberculotic action of some phenothiazine derivatives in vitro. Zentralbl Bakteriol Orig A 1977; 239: 521-526.
9. Kristiansen JE, Vergmann B. The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta Pathol Microbiol Immunol Scand B 1986; 94: 393-398.
10. Ratnakar P, Rao SP, Sriramarao P, Murthy PS. Structureantitubercular activity relationship of phenothiazine-type calmodulin antagonists. Int Clin Psychopharmacol 1995; 10: 39-43.
11. Crowle AJ, Douvas GS, May MH. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38: 410-419.
12. Amaral L, Kristiansen JE, Abebe LS, Millet W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for the initial therapy of freshly diagnosed tuberculosis. J Antimicrob. Chemother 1996; 38: 1049-1953.
13. Ordway D, Viveiros M, Leandro C, Amaral L. Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-922.
14. Martins M, Viveiros M, Amaral L. Sila Compound 421, an Inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular XDRTB. Int J Antimicrob Agents 2008; 33: 479-482.
15. Martins M, Viveiros M, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In vivo 2007; 21:771-776.
16. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010; 5(9). pii: e12640.
17. Bettencourt-Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-228.
18. Abbate E, Vescovo M, Natiello M, Cufré M, Garcia A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivos. Revista Argentina de Medicina Respiratoria 2007; 1: 19-25.
19. Amaral L, Martins A, Molnar J, Kristiansen JE, Martins M, Viveiros M, et al. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In vivo 2010; 24: 409-424.
20. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 2008; 65: 1029-1038.
21. Thanacoody HK. Thioridazine: Resurrection as an antimicrobial agent? Br J Clin Pharmacol 2007; 64: 566-574.
22. Amaral L, Viveiros M, Kristiansen JE. "Non-Antibiotics": Alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 2006; 7: 887-891.
23. Amaral L, Martins M, Viveiros M. Thioridazine: Alternative and potentially effective therapy of the XDR-TB patient. Lett Drug Discov Design 2011; 8: 130-132.
24. Amaral L, Boeree M, Gillespie SH, Udwadia Z, van Soolingen D. Editorial: Thioridazine cures XDR TB: The need for Global Clinical Trials For therapy of XDR TB is now. Int J Antimicrob Agents 2010; 35: 524-526.
25. Rodrigues L, Ramos J, Couto I, Amaral L, Viveiros M. Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiology 2011; 11:35 [Epub ahead of print]
26. Viveiros M, Martins M, Couto I, Rodrigues L, Machado D, Portugal I, et al. Molecular tools for rapid identification and novel effective therapy against MDR/XDR TB infections. Exp Rev of Anti-infect Therap 2010; 8: 465-480.
27. Martins M, Viveiros M, Couto I, Amaral L. Targetting the human macrophage for enhancement of killing of intracellular XDRTB and MDRTB. Int J Tuberculosis Lung Dis 2009; 13: 569-573.
28. Martins M, Viveiros M, Amaral L. The TB Laboratory of the future: The role of the macrophage in the selection of agents that can be used for the successful therapy of an XDRTB infection. Future Microbiol 2008; 3: 135-144.
29. Sohaskey CD. Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J Bacteriol 2008; 190: 2981-6.
30. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 2010;5(4): e10069.
31. Amaral L, Molnar J. Potential therapy of XDRTB with Thioridazine a drug beyond patent protection but eligible for patent as "New Use". Rec Pat Anti-Infect Drug Discov 2010; 5: 109-114.